A platform technology that enables the coating of biological and non-biological surfaces with a matrix capable of sustained release of various active agents currently applied systemically or topically, thereby increasing effectiveness and reducing...

A platform technology that enables the coating of biological and non-biological surfaces with a matrix capable of sustained release of various active agents currently applied systemically or topically, thereby increasing effectiveness and reducing side effects caused by the drug. Keywords: sustained release

Increases effectiveness and reduces side effects of drug treatments

Category	Dental care, Drug delivery
Development Stage	Clinical proof of concept established
Patent Status	Four U.S. patents (and international counterparts) have been granted: 5,116,603; 5,989,522; 5,403,577; 5,849,266
Market Size	Oral health care market more than $1 billion; Dental supplies industry in US is $17.2 billion

Highlights

• Topical composition for the mouth and oesophageal area that allows sustained release of antibacterial agents  to reduce the pathogenic micro-organisms that cause disease
• Prolongs duration of active agents in the oral cavity while increasing effectiveness and reducing side effects
• Applications: Oral care for treatment of periodontal diseases, caries, stomatitis, hypersensitive teeth, halitosis, cosmetic treatments such as teeth whitening, and for use with dental implants

Our Innovation

• Oral compositions that provide sustained, efficient, inexpensive, localized activity in the oral cavity at efficacious levels without deleterious side effects.

Key Features

• Improves patient compliance; necessitates fewer applications of medication
• Controls concentration of drug and duration of active agent at target site
• Minimizes side effects by enabling lower drug dosage
• Avoids systemic intervention

Development Milestones

• Clinical proof of the concept using sustained drug delivery systems in preventing and treating dental caries and hypersensitive teeth showed no toxicity
• In vitro and in vivo studies have demonstrated the efficacy of TOSRD

The Opportunity

• More than 90% of the U.S. population over the age of 13 is affected with dental diseases such as caries, gingivitis and periodontal disease. These oral infections often require the continuous use of drugs for treatment and prevention.
• Dental cosmetics, a growing segment of treatment, require the use of drugs; US demand for dental supplies will grow 5.5 percent annually through 2010 based on favorable demographics and a strong interest in cosmetic dentistry

project-id 7-2006-165

Four U.S. patents (and international counterparts) have been granted:
5,116,603; 5,989,522; 5,403,577; 5,849,266